CSL (CSL) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
18 Jan, 2026Opening remarks and agenda
The meeting was held in a hybrid format, with both in-person and remote participation options, and included procedural instructions for voting and Q&A.
Chair Brian McNamee and Company Secretary Fiona Mead welcomed attendees and outlined the meeting's structure, including online participation and Q&A procedures.
The agenda included board introductions, a business and performance review, formal business items, and a Q&A session.
Financial performance review
Revenue reached US$14.8 billion, up 11% at constant currency; NPATA was US$3 billion, up 15%; net profit after tax up 25%.
Gross profit rose to US$8 billion, maintaining a gross margin above 54%.
Net profit after tax for FY2024 was $2.64 billion, with a final dividend of $2.64 per share.
R&D investment reached US$1.4 billion, up 12% year-on-year; R&D costs at 12% of sales.
Capital expenditure for property, plant, and equipment showed a 31% reduction in FY24.
Board and executive committee updates
Two new non-executive directors, Samantha Lewis and Elaine Sorg, joined the board in 2024; Dr. Brian Daniels to join in December.
Professor Duncan Maskell will retire from the board at the end of the meeting.
Board comprises a diverse group of non-executive directors and the CEO, Paul McKenzie.
CEO Paul McKenzie addressed strategic progress and operational highlights.
The board emphasized the need for global talent and skills in risk management, science, digital, and cybersecurity.
Latest events from CSL
- Strong FY25 results, $2.92 dividend, $500M+ savings plan, and Seqirus demerger deferred.CSL
AGM 20259 Jul 2026 - Key therapies advance as R&D pivots, innovates, and expands a patient-focused pipeline.CSL
Investor Update8 Jul 2026 - FY24 NPATA up 15% to $3B; FY25 guidance: 5–7% revenue and 10–13% NPATA growth.CSL
H2 20248 Jul 2026 - NPAT down 81% on US$8.3B revenue as impairments hit, but FY26 guidance is maintained.CSL
H1 20265 Jun 2026 - Strong FY25 growth, major transformation, Seqirus demerger, and robust FY26 outlook.CSL
H2 20255 Jun 2026 - Revenue up 5% to US$8.48B, NPATA up 5%, strong Behring/Vifor, Seqirus down on US flu rates.CSL
H1 20255 Jun 2026 - FY26 guidance lowered, $5B impairments expected, and transformation initiatives accelerate.CSL
Investor update11 May 2026 - Growth accelerates with US recovery, new vaccine launches, and global expansion in key markets.CSL
CMD 2025 Part 13 Feb 2026 - High single-digit IG and NPAT growth targeted, driven by efficiency, innovation, and portfolio expansion.CSL
CMD 2025 Part 210 Dec 2025